About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Method to Detect Circulating Tumor Cells Developed

by Colleen Fleiss on August 9, 2019 at 9:47 AM
Font : A-A+

New Method to Detect Circulating Tumor Cells Developed

An ultrasensitive method for the direct detection of circulating tumor cells in blood samples has been developed by scientists and published in the journal Angewandte Chemie. It is based on the amplified, time-resolved fluorescence measurement of luminescent lanthanide ions released from nanoparticles that bind specifically to tumor cells.

Conventional techniques for the detection of circulating tumor cells require complicated enrichment before detection because a sample of 10 million blood cells only contains about one tumor cell. In contrast, the new method developed by a team working with Xiaorong Song, Xueyuan Chen, and Zhuo Chen, at Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fujian Agriculture and Forestry University, and Fujian Cancer Hospital (Fuzhou, Fujian, China), works with no enrichment step and directly detects circulating tumor cells in blood samples. The technique is based on a so-called "dissolution-enhanced time-resolved photoluminescence" and uses fluorescing nanoparticles made of lanthanide europium complex.

Advertisement


First the researchers produced antibodies against the epithelial cell adhesion molecule (EpCAM, which is a glycoprotein that is present in very high numbers on the surfaces of many tumor cells and acts as a diagnostic marker for cancer). These antibodies were applied as a coating in the wells of microplates, causing tumor cells contained in the blood sample to remain stuck deep in the wells as other blood components were removed.

The scientists coated the europium-containing nanoparticles with the same antibodies. This caused large numbers of the nanoparticles, added in solution, to specifically bind to the tumor cells. A subsequently added "developer" dissolved the nanoparticles, releasing myriad europium ions. These were immediately bound and tightly locked up by other components of the developer solution. This resulted in a manifold amplification of the fluorescence.
Advertisement

Another essential advantage of this method is that europium ions are very long-lived fluorophores that continue to fluoresce for several microseconds after excitation with a flash of light. Because the measurements are time-resolved, it is possible to start the measurement with a delay. Background signals caused by the autofluorescence of cell components only continue for a few nanoseconds and fade before the measurement begins. This increases the sensitivity of the measurements, making it possible for the researchers to detect a single tumor cell per microplate well.

Tests with blood samples from cancer patients registered as few as 10 cells per milliliter of blood. Fourteen out of fifteen cancer patients were correctly identified by this new method. The number of tumor cells in the samples correlated strongly with the stage of cancer in each patient.

Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Combination Therapy may Benefit Leukemia Patients
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
 Myelofibrosis: New Drugs to Revolutionize Treatment
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
 Blood Vessels Can Kill Cancer Cells and Stop Breast Cancer Spread
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
 Weed Killer Agent Orange May Increase the Risk of Blood Cancer Among Veterans
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Two Years: Optimal Duration of Immunotherapy in Advanced Lung Cancer
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

New Method to Detect Circulating Tumor Cells Developed Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests